News

As per the termination, all rights to develop and commercialize the product were returned to the company in exchange for Talon’s right to receive certain royalty payments in

Under terms of the agreement, Genzyme will market and promote Veracyte’s Afirma Thyroid FNA Analysis, a novel approach for improved thyroid nodule diagnosis, in the US and, subsequently,

The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment (PRESENT) study will enroll approximately 700 breast cancer patients. The

The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (PML). The new label

BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule, the company said. The glycoprotein CD14 on the surface of human macrophages is important

The NSCLC trial evaluated four dose levels of IMO-2055 in combination with standard doses of Tarceva and Avastin in thirty-three patients. In the trial the patients were evaluable

Under the partnership deal, Patheon will possess rights to market Procaps’ soft gel technology and manufacturing capabilities in North America, Europe and Asia. Patheon CEO Jim Mullen said

Tesetaxel is a novel, orally absorbed taxane that has been evaluated in a completed or ongoing Phase 2a/Phase 2b clinical trials. The Phase 2b study enrolled 41 gastric

The company’s first collection is Vitality, a line of accessories for medication and pill management. The nine products in Sabi’s Vitality line, include: Carafe, Chop Crushfolio, Grande Carafe,